HTL Biotechnology inaugurates a new production line dedicated to sterile Hyaluronic Acid
As part of National Biomanufacturing Day 2025, HTL Biotechnology inaugurates a new production line dedicated to Hyaluronic Acid.
Read our news
-
Press releases March 10, 2022GelMEDIX investment
HTL announces its incubator’s equity investment in GelMEDIX, an early-stage biotech aiming at revolutionizing ocular and regenerative therapies.
-
Press releases February 28, 2022Montagu as new investor
HTL announces Montagu as new investor alongside its historical shareholders, Naxicap and Téthys Invest.
-
Press releases September 30, 2021HTL launches a new bioproduction unit HTL4
HTL launches a new, cutting-edge bioproduction unit for pharmaceutical-grade biopolymers.
-
Press releases September 14, 2021BMG Pharma and HTL sign a development agreement
BMG Pharma and HTL sign a development agreement to manufacture BMG’s new biopolymer based on the Hyaluromimethic® Technology
-
Press releases September 8, 2021Eirion Therapeutics Announces Strategic Agreement
Eirion Therapeutics Announces Strategic Agreement for HTL Biotechnology to Become Eirion’s Exclusive Botulinum API Manufacturer.
-
Press releases May 10, 2021Terasaki Institute Memorandum of Uderstanding
HTL Biotechnology and Terasaki Institute for Biomedical Innovation announce Memorandum of Understanding for research in translational biomaterials.
-
Press releases April 13, 2021HTL Biotechnology & Echelon Biosciences strategic partnership
HTL Biotechnology and Echelon Biosciences Inc. announce strategic partnership to advance biopolymer platform and hyaluronic acid research tools